DOCSLIB.ORG

Kite Pharma, Inc. (Exact Name of Registrant As Specified in Its Charter)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kite Pharma, Inc. (Exact Name of Registrant As Specified in Its Charter) S-1/A Page 1 of 205 Table of Contents As filed with the Securities and Exchange Commission on December 9, 2014 Registration No. 333-200615 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Kite Pharma, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2836 27-1524986 (State or Other Jurisdiction of (Primary Standard Industrial (I.R.S. Employer Incorporation or Organization) Classification Code Number) Identification Number) 2225 Colorado Avenue Santa Monica, California 90404 (310) 824-9999 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices) Arie S. Belldegrun, M.D. President, Chief Executive Officer, Chairman, Founder Kite Pharma, Inc. 2225 Colorado Avenue Santa Monica, California 90404 (310) 824-9999 (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service) Copies to: Charles S. Kim, Esq. Donald J. Murray, Esq. Charles J. Bair, Esq. Covington & Burling LLP Cooley LLP The New York Times Building 1333 2nd Street, Suite 400 620 Eighth Avenue Santa Monica, California 90401 New York, New York 10018 (310) 883-6400 (212) 841-1000 Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer _ (Do not check if a smaller reporting company) Smaller reporting company CALCULATION OF REGISTRATION FEE PROPOSED PROPOSED MAXIMUM MAXIMUM AGGREGATE AGGREGATE AMOUNT OF TITLE OF EACH CLASS OF AMOUNT TO BE OFFERING PRICE OFFERING REGISTRATION SECURITIES TO BE REGISTERED REGISTERED(1)PER SHARE (2)PRICE (1)(2)FEE (3) Common Stock, $0.001 par value per share 3,450,000 $43.75 $150,937,500 $17,538.94 (1) Includes offering of additional shares that the underwriters have the option to purchase. (2) Estimated solely for the purpose of calculating the registration fee based on the average of the high and low prices for the Registrant’s common stock on The NASDAQ Global Select Market on December 8, 2014, pursuant to Rule 457(c) under the Securities Act of 1933, as amended. (3) A registration fee of $16,035.60 has been previously paid in connection with this registration statement. The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine. http://cfdocs.btogo.com:27638/cf/drv10/pub/edgar/2014/12/09/0001193125-14-437675/d... 12/09/2014 S-1/A Page 2 of 205 Table of Contents The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted. SUBJECT TO COMPLETION, DATED DECEMBER 9, 2014 PRELIMINARY PROSPECTUS 3,000,000 Shares Common Stock Kite Pharma, Inc. is offering 3,000,000 shares of its common stock. Our common stock is listed on The NASDAQ Global Select Market under the symbol “KITE.” On December 8, 2014, the last reported sale price of our common stock on The NASDAQ Global Select Market was $44.39 per share. We are an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. Investing in our common stock involves risks. See “Risk Factors” beginning on page 12. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. PER SHARE TOTAL Public Offering Price $$ Underwriting Discount and Commissions(1) $ $ Proceeds to Kite Pharma, Inc. (before expenses) $ $ (1) We have agreed to reimburse the underwriters for certain expenses. See “Underwriting.” We have granted the underwriters an option for a period of 30 days to purchase up to an additional 450,000 shares of common stock at the price to the public less the underwriting discount. If the underwriters exercise the option in full, the total underwriting discount and commissions payable by us will be $ , and the total proceeds to us, before expenses will be $ . The underwriters expect to deliver the shares of common stock to purchasers on or about , 2014. Jefferies Credit Suisse Cowen and Company Stifel Prospectus dated , 2014 http://cfdocs.btogo.com:27638/cf/drv10/pub/edgar/2014/12/09/0001193125-14-437675/d... 12/09/2014 S-1/A Page 3 of 205 Table of Contents TABLE OF CONTENTS PAGE Prospectus Summary 1 Risk Factors 12 Special Note Regarding Forward-Looking Statements 44 Use of Proceeds 46 Market Price of Common Stock 47 Dividend Policy 48 Capitalization 49 Dilution 51 Selected Financial Data 53 Management’s Discussion and Analysis of Financial Condition and Results of Operations 54 Business 65 Management 96 Executive and Director Compensation 105 Certain Relationships and Related Party Transactions 113 Principal Stockholders 117 Description of Capital Stock 120 Shares Eligible for Future Sale 124 Material U.S. Federal Income Tax Consequences to Non-U.S. Holders of Our Common Stock 126 Underwriting 129 Legal Matters 137 Change in Independent Accountants 137 Experts 137 Where You Can Find Additional Information 137 Index to Financial Statements F-1 Neither we nor any of the underwriters has authorized anyone to provide you with information different from, or in addition to, that contained in this prospectus or any free writing prospectus prepared by or on behalf of us or to which we may have referred you in connection with this offering. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor any of the underwriters is making an offer to sell or seeking offers to buy these securities in any jurisdiction where or to any person to whom the offer or sale is not permitted. The information contained in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or of any sale of shares of our common stock and the information in any free writing prospectus that we may provide you in connection with this offering is accurate only as of the date of that free writing prospectus. Our business, financial condition, results of operations and future growth prospects may have changed since those dates. i http://cfdocs.btogo.com:27638/cf/drv10/pub/edgar/2014/12/09/0001193125-14-437675/d... 12/09/2014 S-1/A Page 4 of 205 Table of Contents This prospectus includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. For investors outside the United States: neither we nor any of the underwriters has done anything that would permit this offering or possession or distribution of this prospectus or any free writing prospectus we may provide to you in connection with this offering in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus and any free writing prospectus outside of the United States. ii http://cfdocs.btogo.com:27638/cf/drv10/pub/edgar/2014/12/09/0001193125-14-437675/d... 12/09/2014 S-1/A Page 5 of 205 Table of Contents PROSPECTUS SUMMARY This summary highlights information contained in other parts of this prospectus.
Load more

Recommended publications
  • Tishman Speyer and Bellco Capital Launch Breakthrough Properties, a First-Of-Its-Kind Global Life Sciences Real Estate Platform
    FROM: TISHMAN SPEYER Rubenstein Communications, Inc. – Public Relations Contact: Steven Rubenstein (212) 843-8043 Rick Matthews (212) 843-8267 BELLCO CAPITAL Contact: Leah Couvelier (213) 304-9333 Tishman Speyer and Bellco Capital Launch Breakthrough Properties, a First-of-Its-Kind Global Life Sciences Real Estate Platform Unique Collaboration Combines First-Hand Biotechnology Entrepreneurship and Scientific Research Experience with Unsurpassed Commercial Real Estate Development Capabilities Newly-Formed Joint Venture Acquires its First Development Site, in Boston’s Seaport District New York/Los Angeles/Boston – July 16, 2019 - Tishman Speyer, one of the world’s leading developers, owners, operators and asset managers of first-class real estate, and Bellco Capital (“Bellco”), an investment firm founded by biotechnology entrepreneurs Drs. Rebecka and Arie Belldegrun, have formed Breakthrough Properties (“Breakthrough”). The new company will acquire, develop and operate life science properties in leading technology centers around the world to support scientific innovation across biotechnology, agriculture and nutrition. Board Co-Chairs for Breakthrough are Bellco’s Arie Belldegrun and Tishman Speyer President & CEO Rob Speyer. Dan Belldegrun, a long-term member of Tishman Speyer’s Acquisitions and Development team, has been appointed Chief Executive Officer. The partners also announced today that Breakthrough has acquired its first property, taking advantage of Tishman Speyer’s deep roots and expertise as a commercial real estate developer and operator in the Boston market. The development site is strategically located by the Red Line on a one-acre parcel along the A Street corridor in Boston’s Seaport District and comes with 250,000 square feet of development rights. Completion of the project is anticipated in 2021.
    [Show full text]
  • Jefferies Global Healthcare Conference June 2, 2015 Forward Looking Statements / Safe Harbor
    Jefferies Global Healthcare Conference June 2, 2015 Forward Looking Statements / Safe Harbor To the extentstatements contained in this presentation are not descriptionsof historical facts regarding Kite Pharma, Inc. (“Kite,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward- looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding: (i) the success, cost and timing of our product development activities and clinical trials; (ii) the ability and willingness of the National Cancer Institute (NCI) to continue research and development activities relating to our product candidates; (iii) our ability to obtain and maintain regulatory approval of KTE-C19 and any other product candidates; (iv) our ability to obtain funding for our operations and further development and commercialization of our product candidates; (v) our plans to research and discover
    [Show full text]
  • Key Metrics for Recent Technology and Life Sciences Initial Public Offerings
    H1 2014 Key Metrics for Recent Technology and Life Sciences Initial Public Offerings H1 2014 Key Metrics for Recent Technology and Life Sciences Initial Public Offerings H1 2014 Survey Introduction and Background This report has been developed as a resource for our clients and friends interested in understanding recent IPO activity of technology and life sciences companies. This information comprises a number of graphs and charts reflecting selected statistics that we believe provide useful information about activity in these markets. This is followed by the listing of technology and life sciences IPOs priced in the first half of 2014 and second half of 2013. We hope that you find this useful. Please contact Daniel J. Winnike at [email protected] or Jeffrey R. Vetter at [email protected] if you care to discuss this information or, as always, contact members of your client service team for more information. Survey Contents Survey Results ..................................................................................................................................................... 2 Offerings Completed ............................................................................................................................................. 3 Size of Offerings, Red Herring Midpoint ................................................................................................................. 4 Size of Offerings, Final IPO Price ...........................................................................................................................
    [Show full text]
  • Investment Thesis for Kite Pharma, Inc. (Nasdaq: Kite)
    SAF/No.14/March 2017 Studies in Applied Finance INVESTMENT THESIS FOR KITE PHARMA, INC. (NASDAQ: KITE) Samantha Semenkow Johns Hopkins Institute for Applied Economics, Global Health, and the Study of Business Enterprise Investment Thesis for Kite Pharma, Inc. (Nasdaq: KITE) by Samantha Semenkow Investment Thesis for Kite Pharma, Inc. (Nasdaq: KITE) By Samantha Semenkow Disclaimer: These research reports are primarily student reports for academic purposes and are not specific recommendations to buy or sell a stock. Potential investors should consult a qualified investment advisor before making an investment. About the Series The Studies in Applied Finance series is under the direction of Professor Steve H. Hanke ([email protected]), Co-director of The Johns Hopkins Institute for Applied Economics, Global Health, and the Study for Business Enterprise, and Dr. Hesam Motlagh ([email protected]), a Fellow at the Johns Hopkins Institute for Applied Economics, Global Health, and the Study of Business Enterprise. This working paper is one in a series on Applied Financial Economics that focuses on company valuations. The authors are mainly students at The Johns Hopkins University and The Johns Hopkins School of Medicine in Baltimore, MD who have conducted their work at the institute as undergraduate and graduate researchers. About the Author Samantha Semenkow ([email protected]) is a PhD candidate in the Pathobiology Graduate Program at The Johns Hopkins School of Medicine in Baltimore, MD. She conducted the research for this paper while serving as Professor Hanke’s research assistant at The Johns Hopkins Institute for Applied Economics, Global Health, and the Study of Business Enterprise during the Fall of 2016.
    [Show full text]
  • Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
    August 28, 2017 Gilead Sciences to Acquire Kite Pharma for $11.9 Billion -- Immediately Positions Gilead as a Leader in Cell Therapy -- -- Kite's Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU -- -- Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation -- -- Leverages Gilead's Expertise in Rapidly Advancing Therapies to Address Unmet Patient Needs -- FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both the Gilead and Kite Boards of Directors and is anticipated to close in the fourth quarter of 2017. The transaction will provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year three and accretive thereafter. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170828005415/en/ Kite is an industry leader in the emerging field of cell therapy, which uses a patient's own immune cells to fight cancer. The company has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. Kite's most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by the U.S.
    [Show full text]
  • Axelrod V. Kite Pharma, Inc. Et
    Case 2:17-cv-06684 Document 1 Filed 09/11/17 Page 1 of 26 Page ID #:1 1 Rosemary M. Rivas (State Bar No. 209147) Email: [email protected] 2 LEVI & KORSINSKY, LLP 44 Montgomery Street, Suite 650 3 San Francisco, California 94104 Telephone: (415) 291-2420 4 Facsimile: (415) 484-1294 5 Counsel for Plaintiff Merry Axelrod 6 7 8 UNITED STATES DISTRICT COURT 9 FOR THE CENTRAL DISTRICT OF CALIFORNIA 10 MERRY AXELROD, individually and on Case No. 2:17-cv-6684 behalf of all others similarly situated, 11 CLASS ACTION Plaintiff, 12 CLASS ACTION COMPLAINT FOR v. VIOLATION OF SECTIONS 14(d)(4), 13 14(e), AND 20(a) OF THE KITE PHARMA, INC., ARIE SECURITIES EXCHANGE ACT OF 14 BELLDEGRUN, DAVID BONDERMAN, 1934 FARAH CHAMPSI, IAN CLARK, ROY 15 DOUMANI, FRANZ HUMER, JOSHUA JURY TRIAL DEMANDED A. KAZAM, RAN NUSSBAUM, JON 16 PEACOCK, STEVEN B. RUCHEFSKY, OWEN N. WITTE, GILEAD SCIENCES, 17 INC., and DODGE MERGER SUB, INC., 18 Defendants. 19 20 Plaintiff Merry Axelrod (“Plaintiff”), by her attorneys, alleges upon information 21 and belief, except for her own acts, which are alleged on knowledge, as follows: 22 INTRODUCTION 23 1. Plaintiff brings this action on behalf of herself and the public stockholders 24 of Kite Pharma, Inc. (“Kite” or the “Company”) against Kite and members of its Board 25 of Directors (collectively, the “Board” or the “Individual Defendants,” as further defined 26 below, and together with the Company “Defendants”) for violations of Section 14(d)(4), 27 15 U.S.C. § 78n(d)(4), of the Securities and Exchange Act of 1934 (the “Exchange Act”), 28 U.S.
    [Show full text]
  • Gene Therapy to Fight a Blood Cancer Succeeds in Major Study Marilynn Marchione, Ap Chief Medical Writer Updated 2:21 Am, Thursday, March 2, 2017
    3/10/2017 Gene therapy to fight a blood cancer succeeds in major study - SFGate http://www.sfgate.com/news/medical/article/Gene-therapy-to-fight-a-blood-cancer-succeeds-in-10964727.php Gene therapy to fight a blood cancer succeeds in major study Marilynn Marchione, Ap Chief Medical Writer Updated 2:21 am, Thursday, March 2, 2017 IMAGE 1 OF 2 In this May 2016 photo provided by Kite Pharma, cell therapy specialists at the company's manufacturing facility in El Segundo, Calif., prepare blood cells from a patient to be engineered in the lab to fight ... more An experimental gene therapy that turns a patient's own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday. In all, 82 percent of patients had their cancer shrink at least by half at some point in the study. Its sponsor, California-based Kite Pharma, is racing Novartis AG to become the first to win approval of the treatment, called CAR-T cell therapy, in the U.S. It could become the nation's first approved gene therapy. A hopeful sign: the number in complete remission at six months — 36 percent — is barely changed from partial results released after three months, suggesting this one-time treatment might give lasting benefits for those who do respond well. "This seems extraordinary ... extremely encouraging," said one independent expert, Dr. Roy Herbst, cancer medicines chief at the Yale Cancer Center.
    [Show full text]
  • Arie Belldegrun, M.D., Facs Bio & Professional Experience
    ARIE BELLDEGRUN, M.D., FACS BIO & PROFESSIONAL EXPERIENCE Arie Belldegrun, M.D., FACS, founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies. Dr. Belldegrun served as Chairman, President, and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017. He has had a distinguished tenure in the life sciences, having been closely involved with the founding and advancement of several successful biopharmaceutical companies. Prior to Kite, Dr. Belldegrun was the founding Vice-Chairman of the Board of Directors and Chairman of the Scientific Advisory Board of Cougar Biotechnology, acquired by Johnson & Johnson in 2009. Dr. Belldegrun also founded and served as Chairman of the Board of Directors of Agensys, acquired by Astellas Pharma Inc. He currently serves as Chairman of Two River Group and UroGen Pharma, Ltd., and previously served as a Board member of Cell Design Labs until its acquisition by Gilead in December 2017. He is currently a member of the Parker Institute for Cancer Immunotherapy Strategic Advisory Group. In addition, Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, he was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. Dr. Belldegrun completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in Urologic Surgery at Harvard Medical School.
    [Show full text]
  • For Immediate Release Pfizer Media Contact: April 3, 2018 Jessica Smith (212) 733-6213 [email protected]
    For immediate release Pfizer Media Contact: April 3, 2018 Jessica Smith (212) 733-6213 [email protected] Pfizer Investor Contact: Chuck Triano (212) 733-3901 [email protected] Allogene Media/Investor Contact: Christine Cassiano (714) 552-0326 [email protected] Pfizer and Allogene Therapeutics Enter Into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio Creates alliance with Allogene Therapeutics, a biotechnology company co-founded and led by former executives of Kite Pharma that is positioned to expedite the development of allogeneic CAR T cell therapy Allogene Therapeutics, a Two River portfolio company, was formed with one of the largest Series A financings in biotechnology of $300 million from a premier investment consortium that includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer and Pfizer Pfizer will hold a 25 percent ownership stake in Allogene Therapeutics NEW YORK, N.Y. and South San Francisco, Calif., April 3, 2018 – Pfizer Inc. (NYSE: PFE) and Allogene Therapeutics, Inc. (Allogene) today announced that the two companies have entered into an asset contribution agreement for Pfizer’s portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR T) therapY, an investigational immune cell therapY approach to treating cancer. Allogene, co-founded and led bY former executives of Kite Pharma, is ideallY positioned to catalYze the development of this allogeneic cell therapY portfolio. Arie Belldegrun, M.D., FACS, Founder and former Chairman, President and Chief Executive Officer of Kite, will serve as Executive Chairman, and David Chang, M.D., Ph.D., former Executive Vice President, Research and Development and Chief Medical Officer of Kite, will serve as President and Chief Executive Officer.
    [Show full text]
  • Rapid Tumor Regression from PD-1 Inhibition After Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory Diffuse Large B-Cell Lymphoma
    Bone Marrow Transplantation (2020) 55:1184–1187 https://doi.org/10.1038/s41409-019-0657-3 CORRESPONDENCE Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma 1 2 2 2 1,3 Brian T. Hill ● Zachary J. Roberts ● Allen Xue ● John M. Rossi ● Mitchell R. Smith Received: 24 January 2019 / Revised: 7 June 2019 / Accepted: 30 June 2019 / Published online: 30 August 2019 © Springer Nature Limited 2019. This article is published with open access To the Editor: large B-cell lymphoma (DLBCL), with strong PD-L1 expression, whose disease did not respond to axi-cel but Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 who experienced rapid tumor regression after receiving sub- chimeric antigen receptor (CAR) T-cell therapy approved by sequent anti-PD-1 therapy. the US Food and Drug Administration for adult patients with ZUMA-1 (NCT02348216) is a multicenter, phase 1/ relapsed/refractory large B-cell lymphoma after ≥2 lines of 2 study of axi‑cel in patients with refractory large B-cell 1234567890();,: 1234567890();,: systemic therapy [1, 2]. In ZUMA-1, the pivotal study of axi- lymphoma [3, 8, 9]. After leukapheresis and manufacturing, cel in refractory large B-cell lymphoma, with a median of patients received low-dose conditioning chemotherapy 27.1 months follow-up, the objective response rate was 83%, (cyclophosphamide 500 mg/m2 and fludarabine 30 mg/m2 including 58% complete responses [3]. Grade ≥3 cytokine intravenously, days −5to−3) and a single intravenous axi- release syndrome (CRS) and neurologic events occurred in cel infusion (target dose, 2 × 106 CAR T cells/kg, day 0).
    [Show full text]
  • Kite Pharma Initiates Phase 1B/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) October 6, 2016 10:15 AM ET First patient enrolled in ZUMA-6 study evaluating safety and efficacy of anti-CD19 CAR (KTE-C19) therapy in combination with anti-PD-L1 monoclonal antibody atezolizumab SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced the first patient was enrolled in ZUMA-6, a Phase 1b/2 clinical study of KTE-C19 in combination with atezolizumab, Genentech's anti-PD-L1 cancer immunotherapy. The trial is designed to evaluate the safety and efficacy of the combination in patients with refractory diffuse large B-cell lymphoma (DLBCL). PD-L1 expression in DLBCL is associated with high-risk disease and poor outcomes. The interaction of PD-L1 and PD-1, which is expressed on KTE-C19, may dampen T-cell activity in some patients. As a result, use of the two compounds in combination could provide a synergistic effect since inhibiting PD-L1 with atezolizumab may enhance and prolong the activity and proliferation of KTE-C19. "The ZUMA-6 combination study is a core element of our broad strategy to optimize KTE-C19 treatment outcomes and to significantly extend the important potential benefits of KTE-C19 monotherapy," said David Chang, M.D., Ph.D., Kite's Executive Vice President, Research and Development, and Chief Medical Officer. "We view the scientific rationale for this combination study as compelling and look forward to advancing the study based on our extensive clinical experience." Kite entered a clinical collaboration in March 2016 with Genentech, a member of the Roche Group, to evaluate the safety and efficacy of KTE-C19 in combination with atezolizumab.
    [Show full text]
  • Arie Belldegrun, MD, FACS Dr. Arie Belldegrun Has Been a Leader In
    Arie Belldegrun, MD, FACS Dr. Arie Belldegrun has been a leader in developing novel cancer treatments and closely involved with the founding and advancement of several successful private and public biopharmaceutical companies. In 1996, he founded Agensys, Inc., a biotechnology company, and served as its founding Chairman and as a board member until 2007, when it was acquired by Astellas Pharma Inc. From 2003 to 2009, he was the founding Vice-Chairman of the Board of Directors and Chairman of the Scientific Advisory Board of Cougar Biotechnology, Inc., until it was acquired by Johnson & Johnson. Dr. Belldegrun is the Chairman of Arno Therapeutics, Inc., Two River Group, and UroGen Pharma, Ltd. (formerly TheraCoat, Ltd.) and currently serves as a board member of Teva Pharmaceutical Industries Ltd. In addition, at the University of California, Los Angeles (UCLA), Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine. Prior to joining UCLA, he was a research fellow in surgical oncology and immunotherapy at the National Cancer Institute/NIH, working under Dr. Steven A. Rosenberg. Dr. Belldegrun earned his M.D. at the Hebrew University Hadassah Medical School in Jerusalem. He undertook his postgraduate studies in Immunology at the Weizmann Institute of Science, and his residency in Urologic Surgery at the Brigham and Women’s Hospital and Harvard Medical School in Boston, MA. He has authored several books in oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines.
    [Show full text]